Triallelic and epigenetic-like inheritance in human disorders of telomerase

Blood

Volumn 126, Issue 2, 2015, Pages 176-184

  Collopy, Laura C ^a   Walne, Amanda J ^a   Cardoso, Shirleny ^a   De La Fuente, Josu ^b   Mohamed, Mahfuzah ^c   Toriello, Helga ^d   Tamary, Hannah ^e   Ling, Adam J Y V ^a   Lloyd, Timothy ^a   Kassam, Rebecca ^a   Tummala, Hemanth ^a   Vulliamy, Thomas J ^a   Dokal, Inderjeet ^a,f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

^d SPECTRUM HEALTH   (United States)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^f BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME VARIANT; TELOMERASE; RNA; TELOMERASE RNA; TERT PROTEIN, HUMAN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DYSKERATOSIS CONGENITA; ENZYME DEFECT; EPIGENETICS; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; INHERITANCE; MALE; MIDDLE AGED; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TELOMERE SHORTENING; TELOMEROPATHY; CELL CULTURE; COHORT ANALYSIS; FAMILY; GENETIC EPIGENESIS; GENETICS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE;

ALLELES; BASE SEQUENCE; CELLS, CULTURED; COHORT STUDIES; DYSKERATOSIS CONGENITA; EPIGENESIS, GENETIC; FAMILY; HUMANS; INHERITANCE PATTERNS; MOLECULAR SEQUENCE DATA; MUTATION; PEDIGREE; RNA; TELOMERASE;

EID: 84937803170     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633388     Document Type: Article

References (49)

1. Calado R, Young N. Telomeres in disease. F1000 Med Rep. 2012;4:8.
2. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012;13(10): 693-704.
3. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011: 480-486.
4. Knight SW, Heiss NS, Vulliamy TJ, et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol. 1999; 107(2):335-339.
5. Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110(5):1439-1447.
6. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23(2): 215-231.
7. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-460.
8. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA. 1992;89(21): 10114-10118.
9. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-791.
10. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19(18):2100-2110.
11. Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita - update 2015. Eur J Hum Genet. 2015;23(4).
12. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413(6854):432-435.
13. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003; 102(3):916-918.
14. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356(13): 1317-1326.
15. Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA. 2009;106(4):1187-1192.
16. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis. 2005;34(3):257-263.
17. Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA. 2005;102(44):15960-15964.
18. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352(14):1413-1424.
19. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adultonset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007; 104(18):7552-7557.
20. Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011;53(5): 1600-1607.
21. Kirwan M, Vulliamy T, Marrone A, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat. 2009; 30(11):1567-1573.
22. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5): 447-449.
23. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006; 107(7):2680-2685.
24. Tummala H, Kirwan M, Walne AJ, et al. ERCC6L2 mutations link a distinct bonemarrow-failure syndrome to DNA repair and mitochondrial function. Am J Hum Genet. 2014; 94(2):246-256.
25. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37(3):e21.
26. Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica. 2012; 97(4):524-528.
27. Walne AJ, Vulliamy T, Kirwan M, Plagnol V, Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am J Hum Genet. 2013; 92(3):448-453.
28. Collopy LC, Walne AJ, Vulliamy TJ, Dokal IS. Targeted resequencing of 52 bone marrow failure genes in patients with aplastic anemia reveals an increased frequency of novel variants of unknown significance only in SLX4. Haematologica. 2014; 99(7):e109-e111.
29. Basel-Vanagaite L, Dokal I, Tamary H, et al. Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations. Haematologica. 2008;93(6): 943-944.
30. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS ONE. 2010; 5(5):e10680.
31. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res. 2012;13(64): 64-74.
32. Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol. 2000; 10(22):1459-1462.
33. Liu Y, Kha H, Ungrin M, Robinson MO, Harrington L. Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert. Proc Natl Acad Sci USA. 2002;99(6): 3597-3602.
34. Erdmann N, Liu Y, Harrington L. Distinct dosage requirements for the maintenance of long and short telomeres in mTert heterozygous mice. Proc Natl Acad Sci USA. 2004;101(16):6080-6085.
35. MacArthur DG, Balasubramanian S, Frankish A, et al; 1000 Genomes Project Consortium. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012; 335(6070):823-828.
36. Marrone A, Walne A, Tamary H, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood. 2007; 110(13):4198-4205.
37. Du HY, Pumbo E, Manley P, et al. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood. 2008;111(3):1128-1130.
38. Xin ZT, Beauchamp AD, Calado RT, et al. Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood. 2007;109(2): 524-532.
39. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-816.
40. Zaug AJ, Crary SM, Jesse Fioravanti M, Campbell K, Cech TR. Many diseaseassociated variants of hTERT retain high telomerase enzymatic activity. Nucleic Acids Res. 2013;41(19):8969-8978.
41. Zhong FL, Batista LF, Freund A, Pech MF, Venteicher AS, Artandi SE. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell. 2012; 150(3):481-494.
42. Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature. 2012; 492(7428):285-289.
43. Vulliamy TJ, Kirwan MJ, Beswick R, et al. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLoS ONE. 2011;6(9):e24383.
44. Lendvay TS, Morris DK, Sah J, Balasubramanian B, Lundblad V. Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes. Genetics. 1996;144(4):1399-1412.
45. Hughes TR, Evans SK, Weilbaecher RG, Lundblad V. The Est3 protein is a subunit of yeast telomerase. Curr Biol. 2000;10(13):809-812.
46. Katsanis N, Ansley SJ, Badano JL, et al. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science. 2001; 293(5538):2256-2259.
47. Hao LY, Armanios M, Strong MA, et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell. 2005;123(6): 1121-1131.
48. Armanios M, Alder JK, Parry EM, Karim B, Strong MA, Greider CW. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet. 2009;85(6):823-832.
49. De Meyer T, Vandepitte K, Denil S, De Buyzere ML, Rietzschel ER, Bekaert S. A non-genetic, epigenetic-like mechanism of telomere length inheritance? Eur J Hum Genet. 2014;22(1):10-11.